Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-23T09:38:50.367Z Has data issue: false hasContentIssue false

Vancomycin Control Measures at a Tertiary-Care Hospital: Impact of Interventions on Volume and Patterns of use

Published online by Cambridge University Press:  02 January 2015

Mary V. Singer
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Rachel Haft
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Tamar Barlam
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Mark Aronson
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Amy Shafer
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Kenneth E. Sands*
Affiliation:
Divisions of Infectious Diseases and General Internal Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
*
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215

Abstract

OBJECTIVE: Evaluate vancomycin prescribing patterns in a tertiary-care hospital before and after interventions to decrease vancomycin utilization.

DESIGN: Before/after analysis of interventions to limit vancomycin use.

SETTING: 420-bed academic tertiary-care center.

INTERVENTIONS: Educational efforts began August 10, 1994, and involved lectures to medical house staff followed by mailings to all physicians and posting of guidelines for vancomycin use on hospital information systems. Active interventions began November 15, 1994, and included automatic stop orders for vancomycin at 72 hours, alerts attached to the medical record, and, for 2 weeks only, computer alerts to physicians following each vancomycin order. Parenteral vancomycin use was estimated from the hospital pharmacy database of all medication orders. Records of a random sample of 344 patients receiving van-comycin between May 1, 1994, and April 30, 1995, were reviewed for an indication meeting published guidelines.

RESULTS: Vancomycin prescribing decreased by 22% following interventions, from 8.5 to 6.8 courses per 100 discharges (P<.05). The estimated proportion of van-comycin ordered for an indication meeting published guidelines was 36.6% overall, with no significant change following interventions. However, during the 2 weeks that computer alerts were in place, 60% of vancomycin use was for an approved indication.

CONCLUSIONS: Parenteral vancomycin prescribing decreased significantly following interventions, but the majority of orders still were not for an indication meeting published guidelines. Further improvement in the appropriateness of vancomycin prescribing potentially could be accomplished by more aggressive interventions, such as computer alerts, or by targeting specific aspects of prescribing patterns.

Type
Research Article
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ena, J, Dick, RW, Jones, RN, Wenzel, RP. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAAMA 1993;269:598602.Google Scholar
2.Morris, JG Jr, Shay, DK, Hebden, JN, McCarter, RJ Jr, Perdue, BE, Jarvis, W, et al.Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250259.Google Scholar
3.Centers for Disease Control and Prevention. Nosocomial ente-rococci resistant to vancomycin—United States, 1989-1993. MMWR 1993;42:597599.Google Scholar
4.Lam, S, Singer, C, Tucci, V, Morthland, VH, Pfaller, MA, Isenberg, HD. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control 1995;23:170180.Google Scholar
5.Wells, CL, Juni, BA, Cameron, SB, Mason, KR, Dunn, DL, Ferrieri, P, et al.Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:4550.Google Scholar
6.Wade, JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents_a preliminary report. J Hosp Infect 1995;30(suppl):483493.Google Scholar
7.Boyce, JM, Mermel, LA, Zervos, MJ, Rice, LB, Potter-Bynoe, G, Giorgio, C, et al.Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634637.Google Scholar
8.Noskin, GA, Cooper, I, Peterson, LR. Vancomycin-resistant Enterococcus faecium sepsis following persistent colonization. Arch Intern Med 1995;155:14451447.Google Scholar
9.Karanfil, LV, Murphy, M, Josephson, A, Gaynes, R, Mandel, L, Hill, BC, et al.A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195200.Google Scholar
10.Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105113.Google Scholar
11.Handwerger, S, Raucher, B, Altarac, D, Monka, H, Marchione, S, Singh, KV, et al.Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentam- icin. Clin Infect Dis 1993;16:750755.Google Scholar
12.Noble, WC, Viran, Z, Gee, RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195198.Google Scholar
13.Edmond, MB, Wenzel, RP, Pasculle, AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 1996;124:329334.Google Scholar
14.Van der Auwera, P, Pensart, N, Korten, V, Murray, BE, Leclercq, R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:11291136.Google Scholar
15.Shay, DK, Maloney, SA, Montecalvo, M, Banerjee, S, Wormser, GP, Arduino, MJ, et al.Epidemiology and mortality risk of van-comycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:9931000.Google Scholar
16.Frieden, TR, Munsiff, SS, Low, DE, et al.Emergence of van-comycin-resistant enterococci in New York City. Lancet 1993;342:7679.Google Scholar
17.Watanakunakorn, C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of van-comycin resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767769.Google Scholar
18.Evans, M, Kortas, KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee Guidelines. Infect Control Hosp Epidemiol 1996;17:356359.Google Scholar
19.Montecalvo, MA, Horowitz, H, Nadelman, R, Nowakowski, J, Andryshak, C, Colbi, D, et al.Controlling IV vancomycin on an oncology unit by infectious disease consultation. In: The 35th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 09 1995; San Francisco, CA. Abstract N15.Google Scholar
20.Anglim, AM, Klym, B, Byers, KE, Scheld, WM, Farr, BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin resistant Enterococcus faecium. Arch Intern Med 1997;157:11321136.Google Scholar
21.Tornieporth, NG, Roberts, RB, John, J, Hafner, A, Riley, L. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Inf Dis 1996;23:767772.Google Scholar
22.Soumerai, SB, Avorn, J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAAMA 1990;263:549556.Google Scholar
23.Soumerai, SB, Avorn, J. Predictors of physician prescribing change in an educational experiment to improve medication use. Med Care 1987;25:210221.Google Scholar
24.Soumerai, SB, Avorn, J. Economic and policy analysis of university-based drug “detailing.” Med Care 1986;24:313331.Google Scholar
25.Schaffner, W, Ray, WA, Federspiel, CF, Miller, WO. Improving antibiotic prescribing in office practice: a controlled trial of three educational methods. JAMA 1983;250:17281732.Google Scholar